WO2002003978A3 - A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES - Google Patents
A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES Download PDFInfo
- Publication number
- WO2002003978A3 WO2002003978A3 PCT/US2001/021557 US0121557W WO0203978A3 WO 2002003978 A3 WO2002003978 A3 WO 2002003978A3 US 0121557 W US0121557 W US 0121557W WO 0203978 A3 WO0203978 A3 WO 0203978A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- combination
- treatment
- agents useful
- antidiabetic agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037000126A KR100854851B1 (en) | 2000-07-06 | 2001-07-05 | A Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes |
EP01952530A EP1372660A2 (en) | 2000-07-06 | 2001-07-05 | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
HU0301830A HUP0301830A3 (en) | 2000-07-06 | 2001-07-05 | Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
AU2001273271A AU2001273271B2 (en) | 2000-07-06 | 2001-07-05 | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
CA002412142A CA2412142A1 (en) | 2000-07-06 | 2001-07-05 | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
IL15351301A IL153513A0 (en) | 2000-07-06 | 2001-07-05 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
BR0112212-6A BR0112212A (en) | 2000-07-06 | 2001-07-05 | A combination of fbpase inhibitors and antidiabetic agents useful for treating diabetes. |
AU7327101A AU7327101A (en) | 2000-07-06 | 2001-07-05 | A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
MXPA02012713A MXPA02012713A (en) | 2000-07-06 | 2001-07-05 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES. |
JP2002508433A JP2004508297A (en) | 2000-07-06 | 2001-07-05 | Combination agent of FBPase inhibitor and antidiabetic drug useful for treatment of diabetes |
NZ523227A NZ523227A (en) | 2000-07-06 | 2001-07-05 | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
SK6-2003A SK62003A3 (en) | 2000-07-06 | 2001-07-05 | A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
IL153513A IL153513A (en) | 2000-07-06 | 2002-12-18 | Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes |
NO20030034A NO20030034L (en) | 2000-07-06 | 2003-01-03 | A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21653100P | 2000-07-06 | 2000-07-06 | |
US60/216,531 | 2000-07-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002003978A2 WO2002003978A2 (en) | 2002-01-17 |
WO2002003978A3 true WO2002003978A3 (en) | 2003-10-16 |
Family
ID=22807416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/021557 WO2002003978A2 (en) | 2000-07-06 | 2001-07-05 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1372660A2 (en) |
JP (1) | JP2004508297A (en) |
KR (1) | KR100854851B1 (en) |
CN (2) | CN100396283C (en) |
AU (2) | AU2001273271B2 (en) |
BR (1) | BR0112212A (en) |
CA (1) | CA2412142A1 (en) |
CZ (1) | CZ20035A3 (en) |
HU (1) | HUP0301830A3 (en) |
IL (2) | IL153513A0 (en) |
MX (1) | MXPA02012713A (en) |
NO (1) | NO20030034L (en) |
NZ (1) | NZ523227A (en) |
PL (1) | PL365779A1 (en) |
RU (1) | RU2328308C2 (en) |
SK (1) | SK62003A3 (en) |
WO (1) | WO2002003978A2 (en) |
ZA (1) | ZA200300044B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
WO2000014095A1 (en) | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
EP1607401A1 (en) | 2000-03-08 | 2005-12-21 | Metabasis Therapeutics, Inc. | Novel aryl fructose-1,6-Bisphosphatase inhibitors |
WO2003026591A2 (en) | 2001-09-24 | 2003-04-03 | Imperial College Innovations Ltd. | Modification of feeding behavior |
JP4733922B2 (en) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | Correction of eating behavior |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
PL3002283T3 (en) | 2003-12-26 | 2017-10-31 | Kyowa Hakko Kirin Co Ltd | Thiazole derivatives |
CN101005847A (en) * | 2004-08-18 | 2007-07-25 | 症变治疗公司 | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
EP1857118A1 (en) * | 2004-12-13 | 2007-11-21 | Daiichi Sankyo Company, Limited | Medicinal composition for treating diabetes |
TW200738245A (en) * | 2005-08-22 | 2007-10-16 | Sankyo Co | Pharmaceutical composition containing FBPase inhibitor |
WO2007129522A1 (en) * | 2006-04-10 | 2007-11-15 | Daiichi Sankyo Company, Limited | Preparation produced by dry process |
EP2089023A2 (en) | 2006-11-02 | 2009-08-19 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
TWI428346B (en) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CN103665043B (en) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | A kind of tenofovir prodrug and its application in medicine |
UY35065A (en) * | 2012-10-08 | 2014-05-30 | Lg Life Sciences Ltd | COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION |
CN104788350A (en) * | 2014-01-22 | 2015-07-22 | 天津大学 | Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization |
CN106831437B (en) * | 2016-02-03 | 2019-06-21 | 华中师范大学 | Ester type compound and its preparation method and application containing nitroethenyl group |
CN114907285B (en) * | 2021-02-10 | 2023-09-22 | 华中师范大学 | Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009163A2 (en) * | 1989-01-24 | 1990-08-23 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
WO1999047549A1 (en) * | 1998-03-16 | 1999-09-23 | Ontogen Corporation | PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) |
WO2000014095A1 (en) * | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
WO2001052825A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
WO2002000673A1 (en) * | 2000-06-26 | 2002-01-03 | Rodaris Pharmaceuticals Limited | Phosphoglycan messengers and their medical uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6691798A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
US6284748B1 (en) * | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
JP2001515482A (en) * | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase |
-
2001
- 2001-07-05 CA CA002412142A patent/CA2412142A1/en not_active Abandoned
- 2001-07-05 AU AU2001273271A patent/AU2001273271B2/en not_active Ceased
- 2001-07-05 HU HU0301830A patent/HUP0301830A3/en unknown
- 2001-07-05 KR KR1020037000126A patent/KR100854851B1/en active IP Right Grant
- 2001-07-05 CZ CZ20035A patent/CZ20035A3/en unknown
- 2001-07-05 RU RU2003103436/15A patent/RU2328308C2/en not_active IP Right Cessation
- 2001-07-05 PL PL01365779A patent/PL365779A1/en unknown
- 2001-07-05 IL IL15351301A patent/IL153513A0/en unknown
- 2001-07-05 CN CNB018149243A patent/CN100396283C/en not_active Expired - Fee Related
- 2001-07-05 MX MXPA02012713A patent/MXPA02012713A/en not_active Application Discontinuation
- 2001-07-05 JP JP2002508433A patent/JP2004508297A/en active Pending
- 2001-07-05 CN CNA200810098112XA patent/CN101301294A/en active Pending
- 2001-07-05 AU AU7327101A patent/AU7327101A/en active Pending
- 2001-07-05 EP EP01952530A patent/EP1372660A2/en not_active Withdrawn
- 2001-07-05 SK SK6-2003A patent/SK62003A3/en unknown
- 2001-07-05 WO PCT/US2001/021557 patent/WO2002003978A2/en active IP Right Grant
- 2001-07-05 BR BR0112212-6A patent/BR0112212A/en not_active IP Right Cessation
- 2001-07-05 NZ NZ523227A patent/NZ523227A/en not_active IP Right Cessation
-
2002
- 2002-12-18 IL IL153513A patent/IL153513A/en not_active IP Right Cessation
-
2003
- 2003-01-02 ZA ZA200300044A patent/ZA200300044B/en unknown
- 2003-01-03 NO NO20030034A patent/NO20030034L/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990009163A2 (en) * | 1989-01-24 | 1990-08-23 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
WO1999047549A1 (en) * | 1998-03-16 | 1999-09-23 | Ontogen Corporation | PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase) |
WO2000014095A1 (en) * | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
WO2000038666A2 (en) * | 1998-12-24 | 2000-07-06 | Metabasis Therapeutics, Inc. | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
WO2001052825A2 (en) * | 2000-01-21 | 2001-07-26 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
WO2002000673A1 (en) * | 2000-06-26 | 2002-01-03 | Rodaris Pharmaceuticals Limited | Phosphoglycan messengers and their medical uses |
Also Published As
Publication number | Publication date |
---|---|
ZA200300044B (en) | 2004-05-06 |
MXPA02012713A (en) | 2004-09-10 |
KR20030031952A (en) | 2003-04-23 |
NZ523227A (en) | 2005-04-29 |
BR0112212A (en) | 2003-12-30 |
EP1372660A2 (en) | 2004-01-02 |
HUP0301830A2 (en) | 2003-11-28 |
CA2412142A1 (en) | 2002-01-17 |
WO2002003978A2 (en) | 2002-01-17 |
CZ20035A3 (en) | 2003-05-14 |
CN101301294A (en) | 2008-11-12 |
AU7327101A (en) | 2002-01-21 |
IL153513A0 (en) | 2003-07-06 |
KR100854851B1 (en) | 2008-08-27 |
PL365779A1 (en) | 2005-01-10 |
CN100396283C (en) | 2008-06-25 |
HUP0301830A3 (en) | 2007-10-29 |
SK62003A3 (en) | 2003-09-11 |
AU2001273271B2 (en) | 2006-01-05 |
JP2004508297A (en) | 2004-03-18 |
RU2328308C2 (en) | 2008-07-10 |
IL153513A (en) | 2014-07-31 |
CN1599612A (en) | 2005-03-23 |
NO20030034D0 (en) | 2003-01-03 |
NO20030034L (en) | 2003-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002003978A3 (en) | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | |
IL188471A0 (en) | Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus | |
WO2003042246A3 (en) | Inhibitors of the notch signalling pathway for use in the treatment of cancer | |
WO2000038730A3 (en) | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia | |
RS99204A (en) | S-aryl glucoside sglt2 inhibitors and method | |
MXPA03003870A (en) | Combination therapy comprising anti-diabetic and anticonvulsant agents. | |
IL160065A0 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
IL160648A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
IL160630A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2001244399A1 (en) | Gamma-secretase inhibitors | |
WO1999005096A3 (en) | Urokinase inhibitors | |
WO2001085201A3 (en) | Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis | |
YU34199A (en) | Use of gastrointestinal lipase inhibitors | |
AU2002248269A1 (en) | Use of p38 inhibitors for the treatment of inflammation-enhanced cough | |
WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
AU3124300A (en) | Inhibitors of beta-lactamases and uses therefor | |
WO2001056555A3 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
AU2190400A (en) | Inhibitors of beta-lactamases and uses therefor | |
WO2001035979A3 (en) | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity | |
AU2003239025A1 (en) | Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd | |
AUPQ582400A0 (en) | A method of treatment and agents for use therein | |
AU2001285334A1 (en) | Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid | |
WO2002096516A8 (en) | Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease | |
AU1103699A (en) | Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia | |
WO2001000189A3 (en) | Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2412142 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/012713 Country of ref document: MX Ref document number: 153513 Country of ref document: IL Ref document number: 523227 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273271 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01873/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-5 Country of ref document: CZ Ref document number: 2003/00044 Country of ref document: ZA Ref document number: 200300044 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 62003 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037000126 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200300101 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2003103436 Country of ref document: RU Kind code of ref document: A Ref country code: RU Ref document number: RU A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001952530 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018149243 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037000126 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-5 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2001952530 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 523227 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523227 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001273271 Country of ref document: AU |